Chapter 20
Other Respiratory Disorders
Chapter 20
Other Respiratory Disorders
Pulmonary hypertension, or PH, denotes the resting mean pulmonary arterial pressure of 25 mm Hg or higher.
Pulmonary hypertension can be classified into …
Phosphodiesterase inhibitors treat pulmonary arterial hypertension or PAH by inhibiting the activity of the phosphodiesterase enzyme.
Phosphodiesterase 5 …
Endothelin receptor antagonists or ERAs counteract the effects of endothelins, or ETs, to treat pulmonary arterial hypertension or PAH.
ETs are produced …
Prostacyclin receptor agonists are vital in managing pulmonary arterial hypertension.
They mimic prostaglandin I2 and bind to its receptor, IPR, on …
Receptor tyrosine kinase inhibitors or TKIs and calcium channel blockers or CCBs are used for pulmonary arterial hypertension or PAH treatment.
TKIs like …
Oxygen therapy can enhance the quality of life of patients with pulmonary arterial hypertension or PAH who experience hypoxemia or low oxygen levels. This …
Cystic fibrosis, or CF, is an autosomal recessive disorder resulting from mutations in the cystic fibrosis transmembrane conductance regulator or CFTR …
Cystic fibrosis, or CF, is an autosomal genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator or CFTR gene.
CF …
Sublingual route has been widely used to deliver small molecules into the bloodstream and to modulate the immune response at different sites. It has been …
Recently-developed cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs correct surface expression and/or function of the mutant …
As a systemic disease, chronic obstructive pulmonary disease (COPD) affects the respiratory system, inducing restless and exercise dyspnea. It also …